Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience by Rod-Fleury, Thierry et al.
ORIGINAL PAPER
Duration of post-surgical antibiotic therapy for adult
chronic osteomyelitis: a single-centre experience
Thierry Rod-Fleury & Nathalie Dunkel & Mathieu Assal &
Peter Rohner & Phedon Tahintzi & Louis Bernard &
Pierre Hoffmeyer & Daniel Lew & Ilker Uçkay
Received: 11 December 2010 /Accepted: 21 January 2011 /Published online: 12 February 2011
# Springer-Verlag 2011
Abstract
Purpose The optimal duration of concomitant antibiotic
therapy after surgical intervention for implant-free chronic
osteomyelitis is unknown. No randomized data exist.
Available recommendations are based on expert’s opinion.
We evaluated the duration of post-surgical antibiotic
treatment related to remission of chronic osteomyelitis.
Methods This was a retrospective single-centre study at
Geneva University Hospitals with a minimal follow-up of
two years after treatment. We used multivariate logistic
regression analysis with exclusion of pediatric cases and of
implant-related chronic osteomyelitis.
Results A total of 49 episodes of implant-free chronic
osteomyelitis in 49 adult patients were studied. The median
number of surgical interventions was two (range, 1–10).
The median duration of post-debridement antibiotic treat-
ment was eight weeks (range, 4–14 weeks). Thirty-nine
patients (80%) were in remission after a minimal follow-up
of two years. In multivariate logistic regression analysis,
one week of intravenous therapy had the same remission as
two to three weeks (0.2, 0.1–1.9) or ≥ 3 weeks (0.3, 0.1–
2.4). More than six weeks of total antibiotic treatment
equalled ≤ six weeks (0.8, 0.1–5.2).
Conclusions In chronic osteomyelitis in adults, a post-
debridement antibiotic therapy beyond six weeks, or an IV
treatment longer than one week, did not show enhanced
remission incidences. Prospective randomized trials are
required to confirm this observation.
Introduction
Chronic bacterial osteomyelitis is a surgical disease [1, 2].
Various surgical approaches and techniques have been
established [2–7] and experience has been acquired among
orthopedic surgeons and infectious diseases (ID) specialists
worldwide. Whereas expert’s opinion and scientific evidence
is rich for haematogenous childhood osteomyelitis or
implant-related osteomyelitis (surgical site infections), the
optimal antibiotic treatment post-debridement for implant-
free, non-diabetic osteomyelitis among adults remains
unknown [1, 5, 8, 9]. Studies investigated primarily the
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choice of antibiotic agents [8–10], rather than their duration
or route of administration [8, 9]. Different case series
recommend different durations without comparing within or
between the reports [5, 9] and international consensus
guidelines are currently lacking [8].
Experts usually recommend an intravenous (IV) therapy
for four [2] to six weeks [5, 11, 12] followed by an oral
course of additional months or weeks. In practice, long
postsurgical oral treatment regimens are frequent, ranging
from six [8, 10] to ten months [13] or even up to two years
[8]. The rationale for an IV course is to achieve high
elevated serum concentrations, because bone diffusion is
limited for certain groups of antibiotics. To maintain
parenteral treatment, outpatient antibiotic therapy (OPAT)
services [8] have been developed in the United States [14]
and Europe [11, 15]. At the same time, parenteral
medication should be limited as far as possible in order to
save unnecessary costs, prevent catheter-related complica-
tions and to increase patient and nursing comfort. The
estimated proportion of complications attributed to pro-
longed IV course are around 15% [9, 11]. Moreover, the
basis for long periods of supplementary oral treatment
evolved from cases of relapsing osteomyelitis in the 1970s,
which may be less frequent today due to improved surgery
and newly available antibiotics [14]. Yet still, there are no
clinical studies or documented records indicating the
superiority of the four- to six-week course over shorter
durations [5].
We hypothesize that if surgery is adequately performed,
IV antibiotics can be switched to oral administration a few
days later and that a prolonged duration beyond six weeks
is unlikely to be beneficial [5]. In their recent review
regarding duration of antibiotic treatment for osteomyelitis,
Haidar et al. listed small individual reports in animals and
humans that obtained remission of osteomyelitis with
antibiotic durations ranging from one to four weeks [5],
but did not provide their own data. In this retrospective
study, we determine antibiotic duration in relation to the
remission of chronic osteomyelitis. We consider this pilot
analysis as a prerequisite for future prospective randomized
trials.
Methods
Setting and data collection
The Orthopedic Service of Geneva University Hospitals is a
tertiary centre with a septic subunit consisting of 22 acute
care beds. A dedicated team of orthopaedic surgeons,
infectious disease specialists, diabetologists, nurses and
physiotherapists treat patients with osteo-articular infec-
tions. Hyperbaric oxygen is not used.
Databases from the Hospital’s Administrative Coding
and the Septic Orthopaedic Cohort were retrospectively
searched for osteomyelitis among adult orthopaedic
patients free of implants from January 1999 to November
2008. Patients were followed-up until 30 November
2010. Eighty-three variables for each episode were
assessed related to demographic characteristics, immune
suppression, microbiology, surgical and antibiotic treat-
ment modalities and outcomes. An orthopaedic surgeon
(TR) and a biologist with experience in clinical research
(ND) independently recorded each variable on an
EXCEL®-sheet. In case of discordance, a consensus
was negotiated with the infectious disease physician with
experience in osteo-articular infections (IU). The severity
of underlying co-morbidities was assessed by the
Charlson co-morbidity index [16].
The microbiological procedures were unchanged during
the study period and based on the CLSI guidelines [17]. The
study was supported by the Hospital’s Ethics Committee
(No. 08-017R). No informed consent of the included patients
was requested.
Criteria and definitions
Our definition of a chronic osteomyelitis was based on a
surgical [2] (rather than internistic) understanding of
osteomyelitis with bone alterations and abscesses. It
required a minimal symptom duration of three months,
radiological alterations in favour of osteomyelitis, bone
abscesses, and the identification of the same bacteria in
three intraoperative bone samples. Only the first episode of
osteomyelitis at the same localization was recorded;
patients presenting relapsing episodes were excluded. The
presence of a sinus tract or histology was no prerequisite to
include the patient in the study. Exclusion criteria were:
pediatric patients (defined as ≤ 17 years); presence of an
implant in the infected bone; cure by amputation [14, 18];
diabetic foot osteomyelitis, vertebral or skull osteomyelitis,
involvement of fingers or toes only, infection in a bone
modified by prior radiotherapy [10] or osteomyelitis with
pathogens for which the literature provides long-lasting
antibiotic treatments (tuberculosis [19], other mycobacteria,
fungi, or brucellosis).
Remission was defined as complete clinical resolu-
tion of the former infection after a follow-up of two
years. Mechanical sequels were allowed in the defini-
tion “remission”. Recurrence meant new signs of
infection at least two weeks after the end of treatment
for the first episode. Immune suppressed patients were
considered those with diabetes mellitus, HIV infection
with a CD4 count of ≤ 200 cells/mm3, or those
requiring chronic steroid therapy for autoimmune and
rheumatic disorders.
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Statistical analyses
Group comparisons were performed using the Pearson χ2,
Fisher's exact or Wilcoxon rank sum tests. Logistic
regression determined associations with outcome remission.
To adjust for case mix, a multivariate analysis was included
with continuous variables regarding surgical interventions
and antibiotic treatment. In a second step, the duration of
antibiotic treatment was categorized with cut-offs at four,
six, and 12 weeks for total therapy; and at one and
three weeks for intravenous therapy. We included six to
ten predictor variables per outcome event [20]. Variables
were checked for collinearity and interaction; the latter by
Mantel-Haenszel estimates and likelihood ratio tests. We
assessed a possible linearity of antibiotic duration and
remission by linear and logistic regression analyses with
categorized variables. This procedure was performed first
with untransformed variables, and repeated with quadratic
and logarithmic (ln) transformations of these variables.
P values≤0.05 (two-tailed) were regarded as significant.
STATA software (9.0, STATA, USA) was used.
Results
Patients and bones
During the study period a total of 49 chronic osteomy-
elitis episodes, corresponding to the study criteria, could
be determined. Nineteen patients had received a previous
course of unsuccessful antibiotic therapy; however, none
of them underwent prior surgery. Median age of the
patients was 41 years; nine were females. Sixteen
patients (32%) were immune-compromised, of which
ten were due to diabetes mellitus, one due to advanced
HIV infection, and the rest for chronic steroid medica-
tion. Forty-three (85%) patients presented no peripheral
arterial disease; only two revealed a grade III or IV
arterial insufficiency. Median CRP value at admission
was 18 mg/L (range, 3–194 mg/L). Seventeen cases had
normal CRP values (≤ 10 mg/L).
The majority of infections concerned long bones (n=32;
65%), with diaphyseal involvement in 28 cases. The
distribution was as follows: tibia (n =17), femur (6), radius
(4), fibula (4), humerus (3), ulna (2), ischium (2), clavicle
(1), talus (1), and calcaneum (9). Thirty-two episodes
(65%) had a sinus tract on admission, of which 24 were
discharging on admission. According to the Cierny-Mader
classification [21], the majority of infections (39; 80%)
were Cierny grade IV.
Radiological sequestra were witnessed in 15 cases
(31%), while X-rays indicated pathologic evidence in
90%. Histological results were available for 42 cases
(85%) mentioning microorganisms in 16% and inflamma-
tion in 78%.
Pathogens
Current bacterial cultures were positive on a median of three
out of four intraoperative samples. Staphylococcus aureus
was predominant and involved in 29 cases (9 methicillin-
resistant), followed by streptococci: Streptococcus agalactiae
(4), Streptococcus pyogenes (2) and milleri group (3). Other
Gram-positives were Enterococcus faecalis (1). Among
Gram-negatives, we diagnosed osteomyelitis due to Proteus
spp (6), Pseudomonas aeruginosa (6), Enterobacter cloacae
(3), Klebsiella spp (3), and Escherichia coli (1). No anaerobic
pathogen was detected. In 14 cases (29%), osteomyelitis was
polymicrobial. The pathogens were moderately resistant.
Resistances to clindamycin, ciprofloxacin or rifampicin
(for S. aureus) were observed in 33%, 29% and 8%,
respectively.
Surgical treatment
All patients underwent surgical treatment with a median of
two surgical interventions in the operating theatre (range, 1–10
surgeries). In 13 episodes, there was a single intervention; in
11 episodes two interventions. The distribution of interven-
tions was as follows: debridement and lavage (49 cases),
insertion or removal of antibiotic beads (16), intramedullar
reaming (7), use of vacuum-assisted devices (2) and use of
external fixation in four cases (median duration 9 weeks).
Overall, six patients required a later implant in order to achieve
bone stability after clinical remission. Skin and muscular
grafts were needed in ten and 13 cases, respectively.
Antibiotic treatment
All patients received systemic antibiotic therapy and no
severe adverse events were recorded. No antibiotics were
added to the irrigating solutions. Gentamicin beads were
used in 16 cases for a median duration of three weeks. For
parenteral therapy, fluclocaxillin, amoxicillin/clavulanic
acid and vancomycin were the most prescribed agents;
and ciprofloxacin/rifampicin [10] and clindamycin for oral
treatment.
The median duration of total antibiotic therapy was
eight weeks (range, 4–14 weeks); eight episodes were
treated for less than four weeks, nine episodes between four
and six weeks, 20 between seven and 12 weeks, and 12
episodes for>12 weeks. The median duration for parenteral
therapy was eight days (range, 0–42 days); ten episodes
were treated intravenously for a maximum of seven days,
13 between two and three weeks, and 16 episodes for more
than three weeks.
International Orthopaedics (SICOT) (2011) 35:1725–1731 1727
Outcomes
A total of 39 episodes (80%) remained in remission; among
these however 31 with long-term mechanical sequels of
lower degree. The median duration of hospital stay was
six weeks and the median study follow-up time was
7.2 years (range, 2–10 years). Ten cases recurred after a
median delay of ten months. Interestingly, among them four
were due to a different pathogen (3 methicillin-resistant, 1
methicillin-susceptible S. aureus) than the one identified at
first diagnosis. Demographic characteristics were equally
distributed between patients with remission and recurrence,
with one exception. Immune suppression was statistically
more prevalent in the recurrence group (Table 1).
Multivariate analysis
Because of the heterogeneity of the study population and
therapeutic approaches, we performed a multivariate logis-
tic regression analysis to adjust for this case mix.
No demographic or surgical variable showed significant
association with remission (Table 2). Of note was the
observation that steroid-induced immune suppression
showed a trend for more frequent recurrence in the
univariate, but not in the multivariate analysis. Diabetes
mellitus did not influence this trend. No antibiotic related
parameters revealed statistical association with remission:
One week of intravenous therapy had the same success as
two to three weeks (odds ratio 0.2, 95% confidence interval
0.1–1.9) or more than three weeks (0.3, 0.1–2.4). Regard-
ing total antibiotic therapy, a duration stratified at a cut-off
of six weeks was insignificant. Compared to less than six
week’s therapy, a prolonged antibiotic administration
beyond six weeks revealed an odds ratio of 0.8, 95%CI
0.1–5.2. When stratifying the variable “total antibiotic
duration” into more detail, four weeks of total antibiotic
treatment had the same outcome as four to six weeks (0.8,
0.1–14.8), seven to 12 weeks (1.1, 0.1–14.4) or more than
12 weeks (0.8, 0.1–12.3). We equally failed to detect
linearity or a threshold level for antibiotic duration and
remission.
Our final model yielded a non-significant goodness-of-fit
test and a receiver operating curve (ROC) value of 0.8
(95% confidence interval, 0.6–0.9).
Discussion
We report our experience in the management of 49 episodes
of chronic implant-free osteomyelitis among adult ortho-
paedic patients. Our remission incidence of 80% was
similar to the literature [10], where remission “rates” vary
between 60% [14] and 90% [4, 7, 15] with a peak around
80% [8, 9]. Of note, high remission reports are often seen in
Patients, n=49 Recurrence, n=10 Comparison, p valuea Remission, n=39
Female sex 1 8
Median age 48 years 40 years
Median Charlson Index 2 points 1 point
Immune suppressionb 6 0.039 10
- Diabetes mellitus 3 7
- Insulin-dependent diabetes mellitus 0 4
Infection
CRP value on admission 22 mg/L 16 mg/L
Purulent discharge of sinus tract 5 19
Presence of sequestra 1 14
Polymicrobial infection 6 8
Staphylococcus aureus 5 15
- Methicillin-resistant S. aureus 1 7
Gram-negative pathogens 1 12
Treatment
Median no. of surgical interventions 2 2
- Use of gentamicin beads 2 14
- Intramedullar reaming 1 6
Median duration of antibiotic treatment 56 days 56 days
Median duration of IV antibiotic treatment 16 days 8 days
Outcomes
Median length of hospital stay 65 days 44 days
Table 1 Characteristics
and comparison of the patient
groups with recurrence and
remission after treatment
of osteomyelitis
a Only significant p values ≤ 0.05
(two-tailed) are displayed
b Immune suppression = Diabetes
mellitus, steroids, HIV disease
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studies with short follow-up times [3], in acute haemotoge-
nous osteomyelitis in children, or small sample sizes [4, 6, 7].
In general, comparison of treatment modalities in osteomy-
elitis should be interpreted with precaution, since reports are
not based on standardized treatment regimens of osteomye-
litis episodes that include variable definitions such as bones,
pathogens, host factors and different chronicity of drainage
[8, 9].
In our multivariate analysis, no variable was significant-
ly associated with remission, albeit the presence of non-
diabetic immune suppression showed a tendency for an
inverse relationship. Overall, the duration of total post-
debridement antibiotic treatment or of its initial parenteral
part was not associated with the remission incidences. As
continuous variables, antibiotic-related odds ratios and
corresponding confidence intervals were often around one,
indicating equality. As categorized variables, four weeks of
total antibiotic treatment had the same outcome as four to
six weeks or more than 12 weeks. Less than six weeks were
equal to more than six weeks. Therefore, six weeks (if not
less) post-debridement could be sufficient. In the literature,
authors treating for three [22] to six months [10] report the
same remission incidences as other authors treating for
six weeks or less.
Recent retrospective data suggest that regimens with an
early switch to oral antibiotics with good bioavailability are
as effective as prolonged parenteral regimens; as we could
confirm in our study. One week of intravenous (IV) therapy
had the same success as two to three weeks or more.
For osteoarticular infections, several antibiotic agents
have already proven clinical efficacy upon oral intake:
quinolones [10], linezolid, clindamycin, and fusidic acid
combined with rifampin. These drugs have an oral
bioavailability of over 90% [23]. As clinical examples,
Cordero-Ampuero et al. cured 36 arthroplasty infections
with oral antibiotics administered from the start [24], and
Eyichukwu et al. reported successful treatment of chronic
osteomyelitis after surgery and short-term sensitivity-based
IV course of two to three days, followed by oral
administration [13]. A recent Cochrane review included
five trials comparing oral vs. IV antibiotics for chronic
osteomyelitis in adults. There was no statistically signifi-
cant difference in the remission rate [9].
Our study has the following limitations: (i) It was a
retrospective, single-center study with a small and
heterogeneous population. Especially, the small sample
size is an important issue and may hide differences that
would have been seen if the analyses were performed
Variable associated with remission Univariate analysis Multivariate analysis
Odds ratio (95%
confidence interval)
Odds ratio (95%
confidence interval)
Age (continuous variable) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
-Age between 30 and 60 yearsa 1.1 (0.2–6.6) n.a.
-Age over 60 yearsa 0.5 (0.1–2.7) n.a.
Charlson Index (continuous variable) 0.8 (0.5–1.2) n.a.
-Index with more than 2 pointsb 0.6 (0.1–2.9) n.a.
Immune suppressionc 0.2 (0.1–0.9) 0.2 (0.1–1.1)
-Diabetes mellitus 0.5 (0.1–2.5) n.a.
CRP on admission (continuous variable) 1.0 (1.0–1.0) n.a.
Long bone osteomyelitis 0.7 (0.2–3.4) n.a.
Staphylococcus aureus 0.7 (0.2–3.1) n.a.
No. of surgical interventions 0.7 (0.5–1.0) 0.7 (0.5–1.0)
-2 to 3 surgical interventionsd 0.6 (0.1–3.8) 0.2 (0.1–2.9)
-More than 3 surgical interventionsd 0.3 (0.1–1.9) 0.1 (0.1–1.8)
Use of gentamicin beads 2.2 (0.4–12.0) n.a.
Intramedullary reaming 1.6 (0.2–15.4) n.a.
Duration of antibiotic treatment (contin.variable) 1.0 (0.98–1.03) 1.0 (0.98–1.03)
- ≤6 weeks compared to >6 weeks 0.8 (0.2–3.1) 0.8 (0.1–5.2)
- 4 to 6 weeks compared to ≤4 weeks 0.3 (0.1–3.5) 0.8 (0.1–14.8)
- 6 to 12 weeks compared to ≤4 weeks 0.6 (0.1–6.0) 1.1 (0.1–14.4)
- >12 weeks compared to ≤4 weeks 0.7 (0.1–9.5) 0.8 (0.1–12.3)
Duration of IV therapy (continuous variable) 1.0 (0.96–1.03) 0.8 (0.96–1.05)
- 8 to 21 days compared to ≤7 days 0.3 (0.1–1.6) 0.2 (0.1–1.9)
- More than 21 days compared to ≤7 days 0.3 (0.1–2.1) 0.3 (0.1–2.4)
Table 2 Associations of
variables with remission of
osteomyelitis (logistic
regression)
Variables in bold are statistically
significant (two-tailed p
value < 0.05)
n.a.=not available, multivariate
analysis not performed
a Age groups compared to the
group of less than 30 years old
b Charlson index compared to the
group with ≤2 points
c Immune suppression=Diabetes
mellitus, steroid medication, HIV
disease
d Compared to a single surgical
intervention
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with a more numerous patient population. For instance, a
larger sample size would have made it possible to
separate those treated with gentamicin beads and the
immuno-compromised from the others. This would have
improved the quality of our work. However, such a
sample size has never been achieved in the literature for
implant-free osteomyelitis to the best of our knowledge.
According to our estimation, a study population of at
least 300 patients would be required to perform such
separated analyses. Of note, our case series of implant-
free chronic osteomyelitis is one of the largest series
described in adults. (ii) Follow-up time could be too
short. Recurrences of osteomyelitis after several years, if
not decades, have been reported [22], and there is no
internationally accepted minimal follow-up duration.
Some authors argue that chronic osteomyelitis never heals,
and the best you can achieve would be to control the
infection or to get patients asymptomatic. In the literature,
minimal follow-up times range from three months [3] to
one year [7–10, 24] or to two years [4, 15]. Tice et al.
showed that 78% and 95% of all osteomyelitis recurrences
occur within six and 12 months, respectively [14]. Hence,
we consider our individual minimal and median follow-up
times of two and seven years as a strong point of our
study. (iii) Patients with recurrences treated in another
hospital may have been undetected. However, Geneva
University Hospitals are by far the largest and only public
hospitals in the area; we therefore consider this possibility
as low. (iv) The completeness of initial surgical debride-
ment is of paramount importance [4]. Surgeons know how
extensively they should perform this debridement. There
are no retrospective possibilities to estimate the complete-
ness of such a debridement. (v) Staphylococcal small-
colony variants are considered as a risk factor for
persistence of bone infections. We could not assess their
presence, since our specimens had not been stored. (vi)
Our definition of chronic osteomyelitis was rather oriented
on a surgical point of view rather than on a radiological or
internistic definition. Our cases evolved over at least three
months, were only primary episodes, revealed the presence
of bone abscesses and identified a pathogen in every case.
This working definition might be too rigorous. Especially,
the need for pathogen identification excludes culture-
negative cases. However, we intended to be absolutely
sure about chronic infectious osteomyelitis, for which the
confirmation of pathogens in at least three bone samples
(abscesses) was considered as essential for this manuscript. Of
note, the specific literature lacks an internationally accepted
definition [8]. (vii) Despite adjustment for case-mix, we
cannot completely exclude therapeutic decision bias.
Patients, who were doing less well, might have deserved a
longer antibiotic treatment. This theoretical bias reinforces
the need for prospective trials.
Our findings may have implications to tailor such future
randomized trials. If our retrospective results are confirmed,
a shorter or oral antibiotic treatment post-debridement
could further decrease antibiotic consumption, as well as
the related costs, adverse effects and selective pressure for
resistant bacterial pathogens.
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